Interpretive categorical accuracy of fluoroquinolone reference broth microdilution MIC results when testing Streptococcus pneumoniae: selection of a surrogate testing agent

Diagnostic Microbiology and Infectious Disease

Volumn 62, Issue 4, 2008, Pages 460-463

  Sader, Helio S ^a   Koeth, Laura M ^b   Poupard, James A ^c   Jones, Ronald N ^a  

^a JMI LABORATORIES   (United States)

^b Laboratory Specialists Inc   (United States)

^c Pharma Institute of Philadelphia   (United States)

Author keywords

Fluoroquinolones; Gemifloxacin; Levofloxacin; Moxifloxacin; Streptococcus pneumoniae

Indexed keywords

GATIFLOXACIN; GEMIFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ACCURACY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BROTH DILUTION; DRUG ACTIVITY; HUMAN; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FLUOROQUINOLONES; MICROBIAL SENSITIVITY TESTS; REPRODUCIBILITY OF RESULTS; STREPTOCOCCUS PNEUMONIAE;

EID: 56049123175     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2008.08.020     Document Type: Article

References (13)

1. Adam H.J., Schurek K.N., Nichol K.A., Hoban C.J., Baudry T.J., Laing N.M., Hoban D.J., and Zhanel G.G. Molecular characterization of increasing fluoroquinolone resistance in Streptococcus pneumoniae isolates in Canada, 1997 to 2005. Antimicrob. Agents Chemother. 51 (2007) 198-207
2. Andriole V.T. The quinolones: past, present, and future. Clin. Infect. Dis. 41 Suppl 2 (2005) S113-S119
3. Barry A.L., and Jones R.N. Cross susceptibility and absence of cross resistance to cefotetan and cefoxitin. J. Clin. Microbiol. 25 (1987) 1570-1571
4. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A7. 7th ed. (2006), CLSI, Wayne, PA
5. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing, 18th informational supplement, M100-S18 (2008), CLSI, Wayne, PA
6. Fuller J.D., and Low D.E. A review of Streptococcus pneumoniae infection treatment failures associated with fluoroquinolone resistance. Clin. Infect. Dis. 41 (2005) 118-121
7. Jones R.N., and Pfaller M.A. Can antimicrobial susceptibility testing results for ciprofloxacin or levofloxacin predict susceptibility to a newer fluoroquinolone, gatifloxacin? Report from The SENTRY Antimicrobial Surveillance Program (1997-99). Diagn. Microbiol. Infect. Dis. 39 (2001) 237-243
8. Jones R.N., Sader H.S., Fritsche T.R., Hogan P.A., and Sheehan D.J. Selection of a surrogate agent (vancomycin or teicoplanin) for initial susceptibility testing of dalbavancin: results from an international antimicrobial surveillance program. J. Clin. Microbiol. 44 (2006) 2622-2625
9. Moellering J.R.C. The fluoroquinolones: the last samurai?. Clin. Infect. Dis. 41 Suppl 2 (2005) S111
10. National Committee for clinical and Laboratory Standards. Development of in vitro susceptibility testing criteria and quality controls parameters; approved guideline, second edition, M23-A2 (2001), NCCLS, Wayne, PA
11. Schito A.M., and Schito G.C. Levofloxacin, a broad spectrum anti-infective: from Streptococcus pneumoniae to Pseudomonas aeruginosa. J. Chemother. 16 Suppl. 2 (2004) 3-7
12. Schurek K.N., Adam H.J., Hoban D.J., and Zhanel G.G. Call for the international adoption of microbiological breakpoints for fluoroquinolones and Streptococcus pneumoniae. Int. J. Antimicrob. Agents 28 (2006) 266-269
13. Van Bambeke F., Reinert R.R., Appelbaum P.C., Tulkens P.M., and Peetermans W.E. Multidrug-resistant Streptococcus pneumoniae infections: current and future therapeutic options. Drugs 67 (2007) 2355-2382